Mazumdar Claire 4

What Happened

• Claire Mazumdar, CEO of Bicara Therapeutics Inc. (BCAX), received a derivative equity award on Feb 2, 2026 covering 450,000 shares. The Form 4 reports the acquisition at $0.00 (award/grant), i.e., this is a compensation award (stock option-type grant), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-02; Form 4 filed 2026-02-04 (timely).
• Reported amount: 450,000 shares (derivative award) at $0.00 per share.
• Vesting: The shares underlying the option vest in 16 equal quarterly installments beginning Feb 2, 2026 (about 28,125 shares per quarter), subject to continued service. (Footnote from filing.)
• Shares owned after transaction: not specified in the provided filing excerpt.
• No 10b5-1 plan, tax withholding, or immediate sale reported.

Context

• This is a standard executive compensation grant intended to align management with shareholder value over time. Because the award vests over four years, it does not represent an immediate purchase or sale of stock and should be viewed as a retention/compensation event rather than a direct bullish market signal.